Analysis of the Clinical Effect of Concurrent Chemoradiotherapy Com-bined with PD-1 Inhibitor Pabolizumab in the Treatment of Advanced Non-small Cell Lung Cancer
Objective To investigate the clinical value of concurrent chemoradiotherapy combined with programmed cell death protein-1(PD-1)inhibitor(paporizumab)in the treatment of advanced non-small cell lung cancer.Methods From September 2022 to October 2023,70 patients with advanced non-small cell lung cancer admitted to Tengzhou Central People's Hospital of Shandong Province were randomly selected as the research objects.According to the dif-ferent treatment methods,they were divided into two groups,35 cases in each group.The control group was treated with concurrent chemoradiotherapy combined with cisplatin and gemcitabine.The study group was treated with paboli-zumab on the basis of concurrent chemoradiotherapy.The clinical effects of the two groups were evaluated.Results The total effective rate of treatment in the study group(85.71%)was higher than that in the control group(62.86%),and the difference was statistically significant(χ2=4.786,P=0.028).There was no significant difference in the inci-dence of adverse reactions between the two groups(P＞0.05).After treatment,the levels of CD3+,CD4+and CD4+/CD8+in the study group were higher than those in the control group,and the level of CD8+was lower than that in the control group,the differences were statistically significant(all P＜0.05).Conclusion The combination of concurrent chemora-diotherapy and pembrolizumab is an effective and safe treatment for advanced non-small-cell lung carcinoma.
NETL
NSTL
万方数据
